28 June 2021
Consilium Strategic Communications Advises Quanta Dialysis Technologies on $245 Million Series D Funding Round
~ Largest-ever private funding round for a dialysis device company ~
London, 28 June 2021, Consilium Strategic Communications (Consilium), a global leader in strategic healthcare communications and investor relations, is pleased to have supported Quanta Dialysis Technologies (Quanta), on the communication of its oversubscribed $245 million Series D funding round. Quanta is a medical technology leader delivering on its vision for more flexible and accessible dialysis care. The round was led by Glenview Capital and co-led by Novo Holdings and attracted a broad group of new and existing top-tier investors.
Quanta’s award-winning portable hemodialysis system SC+ is the only next-generation system that delivers the performance and dose equivalence of larger, traditional dialysis systems while also offering the portability, digital connectivity and ease-of-use of a next-generation dialysis device. Additionally, Quanta’s companion water purification module works with SC+ as an all-in-one mobile stack allowing dialysis treatments to be delivered in settings with just a standard water supply. This winning proposition positions SC+ to unlock the potential benefits of more flexible and more efficient dialysis delivery models for payors, providers, physicians and patients.
“Consilium has supported Quanta since 2014 and we are delighted to see the company be supported so resoundingly by such high-quality international investors in this landmark raise. This is recognition of the Quanta’s compelling proposition for dialysis patients and a validation of Quanta’s potential to transform kidney care. We are delighted for John and all the team at Quanta.”
Amber FennellPartner and Co-Founder at Consilium Strategic Communications
“Quanta is strongly positioned to help transform kidney care and we are grateful to the Consilium team for their support over the last eight years in helping us communicate our vision.”
John E. MiladChief Executive Officer of Quanta
The funding will allow Quanta to scale up global operations with a focus on the United States, where SC+ received 510(k) clearance from the FDA in December for use in acute and chronic care facilities. The company is investing in significant infrastructure to scale up manufacturing, sales and customer service functions to support use in currently approved care settings within the United States, while also preparing to launch a study to support its future FDA clearance for in-home use within the United States.
The Consilium team was led by Amber Fennell and Matthew Neal and supported by Lindsey Neville, Priit Piip, Priscila Radu and Alexander Bridge. J.P. Morgan served as exclusive placement agent to Quanta for the transaction.
To view Quanta’s announcement, please click here.
For more information, please contact:
Consilium Strategic Communications
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
Follow us: @consiliumhc
About Consilium Strategic Communications
Consilium Strategic Communications is a global leader in strategic healthcare communications and investor relations advisory with offices in Europe and across the US. Consilium's highly skilled team provides strategic, long-term advice to healthcare companies, Boards, senior decision makers and executives on critical communications and IR programmes and stakeholder challenges. The Company has established deep knowledge across all areas of the global healthcare sector through broad experience in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to discrete specialist reputation management projects.
About Quanta and SC+
Quanta is enabling the future of kidney care, with a mission to bring to market solutions that improve the delivery of dialysis and help people live more freely. Headquartered in the UK and with operations in the US, Quanta is a trans-Atlantic, commercial-stage medical technology innovator.
Quanta’s lead product, SC+, is a small and simple, powerful hemodialysis system designed to provide greater freedom and flexibility in the delivery of life sustaining dialysis treatments. In the US, SC+ is FDA cleared for use in acute and chronic care facilities, and in the UK, it is CE marked, where it has been successfully used to treat patients across a range of care settings, from the ICU and the clinic to the home.
The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The simple to-use and digitally connected design of SC+ is intended to empower more patients to take control of their lives with selfcare and home dialysis. Meanwhile, as a compact, portable and versatile device, SC+ provides flexibility to deliver dialysis across a wide range of use environments and prescriptions.
Learn more at https://www.quantadt.com/